Anticoagulation in COVID-19: reaction to the ACTION trial
Lancet
.
2021 Jun 12;397(10291):2226-2228.
doi: 10.1016/S0140-6736(21)01291-5.
Authors
Jeffrey S Berger
1
,
Jean Marie Connors
2
Affiliations
1
Center for the Prevention of Cardiovascular Disease, New York University School of Medicine, New York, NY 10016, USA; New York University Langone Health, New York, NY, USA. Electronic address: jeffrey.berger@nyulangone.org.
2
Brigham and Women's Hospital, Boston, MA, USA.
PMID:
34119049
PMCID:
PMC8192086
DOI:
10.1016/S0140-6736(21)01291-5
No abstract available
Publication types
Comment
MeSH terms
Anticoagulants / adverse effects
COVID-19*
Fibrin Fibrinogen Degradation Products
Hospitals
Humans
SARS-CoV-2
Substances
Anticoagulants
Fibrin Fibrinogen Degradation Products
fibrin fragment D